Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07WEN
|
|||
| Drug Name |
Venglustat
|
|||
| Synonyms |
Ibiglustat; 1401090-53-6; UNII-BLP1XA3FZA; BLP1XA3FZA; (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate; Ibiglustat [INN]; SCHEMBL12615329; YFHRCLAKZBDRHN-MRXNPFEDSA-N; Ibiglustat(Genz-682452 pound(c); GZ-452; SAR402671; ZINC202143443; AKOS027337125; CS-6512; Carbamic acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3S)-1-azabicyclo(2.2.2)oct-3-yl ester; (3S)-1-Azabicyclo(2.2.2)octan-3-yl N-(2-(2-(4-fluorophenyl)-1,3-thiazol-4-yl)propan-2-yl)carbamate; GZ4026
Click to Show/Hide
|
|||
| Indication | Fabry disease [ICD-11: 5C56.01; ICD-9: 272.7] | Phase 2 | [1] | |
| Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [2] | ||
| Gaucher disease [ICD-11: 5C56.0Y; ICD-9: 272.7] | Phase 1 | [3] | ||
| Company |
Genzyme, Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24FN3O2S
|
|||
| Canonical SMILES |
CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)OC3CN4CCC3CC4
|
|||
| InChI |
1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1
|
|||
| InChIKey |
YFHRCLAKZBDRHN-MRXNPFEDSA-N
|
|||
| CAS Number |
CAS 1401090-53-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ceramide glucosyltransferase (UGCG) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Sphingolipid metabolism | |||
| Metabolic pathways | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Pathway Interaction Database | IL2 signaling events mediated by PI3K | |||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036945) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.